Order Article Reprints

Hopkins AM, Kichenadasse G, Abuhelwa AY, McKinnon RA, Rowland A, Sorich MJ. Reply to Auclin et al. Comment on “Hopkins et al. Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial. Cancers 2021, 13, 1176”. Cancers. 2021; 13(15):3763. https://doi.org/10.3390/cancers13153763

Hopkins, Ashley M., Ganessan Kichenadasse, Ahmad Y. Abuhelwa, Ross A. McKinnon, Andrew Rowland, and Michael J. Sorich. 2021. "Reply to Auclin et al. Comment on “Hopkins et al. Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial. Cancers 2021, 13, 1176”" Cancers 13, no. 15: 3763. https://doi.org/10.3390/cancers13153763

Hopkins, A. M., Kichenadasse, G., Abuhelwa, A. Y., McKinnon, R. A., Rowland, A., & Sorich, M. J. (2021). Reply to Auclin et al. Comment on “Hopkins et al. Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial. Cancers 2021, 13, 1176”. Cancers, 13(15), 3763. https://doi.org/10.3390/cancers13153763